Insight Molecular Diagnostics (IMDX) Cost of Revenue (2016 - 2026)

Insight Molecular Diagnostics has disclosed Cost of Revenue across 11 years of filings, most recently posting $17000.0 for Q1 2026.

• Cost of Revenue for Q1 2026 came in at $17000.0, down 98.59% year-over-year; the trailing twelve-month figure through Mar 2026 was -$731000.0 (down 79.17% YoY), and the FY2025 annual result was $1.8 million, up 66.19% from the prior year.
• Cost of Revenue came in at $17000.0 for Q1 2026 at Insight Molecular Diagnostics, up from -$2.3 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $1.4 million in Q3 2025 to a low of -$2.3 million in Q4 2025.
• The 5-year median for Cost of Revenue is $168000.0 (2025), against an average of $84764.7.
• Across the five-year window, Cost of Revenue tumbled 512.96% in 2024 and jumped 3123.26% in 2025, its largest moves.
• Insight Molecular Diagnostics' Cost of Revenue stood at $278000.0 in 2022, then jumped by 47.12% to $409000.0 in 2023, then sank by 512.96% to -$1.7 million in 2024, then tumbled by 36.29% to -$2.3 million in 2025, then surged by 100.74% to $17000.0 in 2026.
• The last three Cost of Revenue figures came in at $17000.0 (Q1 2026), -$2.3 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.